Abstract
The renin-angiotensin system (RAS), an important control system for blood pressure and intravascular volume, also causes left ventricular hypertrophy (LVH) and fibrosis. The main causal mechanism is the increase in blood pressure, which leads to increased left ventricular wall stress; however, aldosterone release from the adrenals and (more controversially) the direct action of angiotensin II on the cardiomyocytes also play a role. Large clinical trials evaluating the blockade of the RAS with angiotensin-converting enzyme inhibitors or angiotensin receptor blockers have demonstrated an ability to prevent progression and induce regression of left ventricular mass, thereby reducing the significant and independent cardiovascular risk conferred by LVH. Regression of left ventricular mass is also achieved by other medication classes, but the RAS blockers have an additional beneficial effect for the same blood pressure reduction, for which the mechanism is not entirely clear. Studies comparing the efficacy of angiotensin-converting enzyme inhibitors versus angiotensin receptor blockers to achieve LVH regression have not demonstrated any clear benefit of one class over the other.
Article PDF
Similar content being viewed by others
References and Recommended Reading
Kearney P, Whelton M, Reynolds K, et al.: Worldwide prevalence of hypertension: a systematic review. J Hypertens 2004, 22:11–19.
Matchar D, McCrory D, Orlando L, et al.: Systematic review: comparative effectiveness of angiotensin-converting enzyme inhibitors and angiotensin II receptor blockers for treating essential hypertension, Ann Intern Med 2008, 148:16–29.
McMullen J, Jennings G: Differences between pathological and physiological cardiac hypertrophy: novel therapeutic strategies to treat heart failure. Clin Exp Pharm Physiol 2007, 34:255–262.
Agabiti-Rosei E, Muiesan ML, Salvetti M: New approaches to the assessment of left ventricular hypertrophy. Ther Adv Cardiovasc Dis 2007, 1:119–128.
Bottini P, Carr A, Prisant M, et al.: Magnetic resonance imaging compared to echocardiography to assess left ventricular mass in the hypertensive patient, Am J Hypertens 1995, 8:221–228.
Young A, Cowan B, Thrupp S, et al.: Left ventricular mass and volume: fast calculation with guide-point modeling on MR images. Radiology 2000, 216:597–602.
Lang RM, Bierig M, Devereux RB, et al.: Recommendations for chamber quantification. Eur J Echocardiography 2006, 7:79–108.
Levy D, Garrison R, Savage D, et al.: Prognostic implications of echocardiographically determined left ventricular mass in the Framingham Heart Study. N Engl J Med 1990, 322:1561–1566.
Schillaci G, Verdecchia P, Porcellati C, et al.: Continuous relation between left ventricular mass and cardiovascular risk in essential hypertension. Hypertension 2000, 35:580–586.
Vakili BA, Okin PM, Devereux RB: Prognostic implications of left ventricular hypertrophy. Am Heart J 2001, 141:334–341.
Ghali J, Liao Y, Cooper R: Influence of left ventricular geometric patterns on prognosis in patients with or without coronary artery disease. J Am Coll Cardiol 1998, 31:1635–1640.
Verdecchia P, Schillaci G, Borgioni C, et al.: Prognostic significance of serial changes in left ventricular mass in essential hypertension. Circulation 1998, 97:48–54.
Mathew J, Sleight P, Lonn E, et al.: Reduction of cardiovascular risk by regression of electrocardiographic markers of left ventricular hypertrophy by the angiotensin-converting enzyme inhibitor ramipril. Circulation 2001, 104:1615–1621.
Tigerstedt R, Bergman P: Niere und kreislauf. Skand Arch Physiol 1898, 8:223–271.
Wolf G: “The road not taken”: role of angiotensin II type 2 receptor in pathophysiology. Nephrol Dial Transplant 2002, 17:195–198.
Bader M, Ganten D: Update on tissue renin-angiotensin systems. J Mol Med 2008, 86:615–621.
Donoghue M, Hsieh F, Baronas E, et al.: A novel angiotensin-converting enzyme-related carboxypeptidase (ACE2) converts angiotensin I to angiotensin 1–9. Circ Res 2000, 87:E1–E9.
Santos R, Ferreira A: Angiotensin-(1–7) and the reninangiotensin system. Curr Opin Nephrol Hypertension 2007, 16:122–128.
Grobe J, Mecca A, Lingis M, et al.: Prevention of angiotensin II-induced cardiac remodeling by angiotensin-(1–7). Am J Physiol Heart Circ Physiol 2007, 292:736–742.
Santos RA, Ferreira AJ, Nadu AP, et al.: Expression of an angiotensin-(1–7)-producing fusion protein produces cardio-protective effects in rats. Physiol Genomics 2004, 17:292–299.
Santos RA, Castro CH, Gava E, et al.: Impairment of in vitro and in vivo heart function in angiotensin-(1–7) receptor Mas knockout mice. Hypertension 2006, 47:996–1002.
Lorell B, Carabello B: Left ventricular hypertrophy: pathogenesis, detection and prognosis. Circulation 2000, 102:470–479.
Mehta P, Griendling K: Angiotensin II cell signaling: physiological and pathological effects in the cardiovascular system. Am J Physiol Cell Physiol 2007, 292:C82–C97.
Reudelhuber T, Bernstein K, Delafontaine P: Is angiotensin II a direct mediator of left ventricular hypertrophy? Time for another look. Hypertension 2007, 49:1196–1201.
Mazzolai L, Nussberger J, Aubert J, et al.: Blood pressure-independent cardiac hypertrophy induced by locally activated renin-angiotensin system. Hypertension 1998, 31:1324–1330.
Xiao H, Fuchs S, Campbell D, et al.: Mice with cardiacrestricted angiotensin-converting enzyme (ACE) have atrial enlargement, cardiac arrhythmia, and sudden death. Am J Pathol 2004, 165:1019–1032.
van Kats J, Methot D, Paradis P, et al.: Use of a biological peptide pump to study chronic peptide hormone action in transgenic mice: direct and indirect effects of angiotensin II on the heart. J Biol Chem 2001, 276:44012–44017.
Paradis P, Dali-Youcef N, Paradis FW, et al.: Overexpression of angiotensin II type I receptor in cardiomyocytes induces cardiac hypertrophy and remodeling. Proc Natl Acad Sci U S A 2000, 97:931–936.
Crowley S, Gurley S, Herrera M, et al.: Angiotensin II causes hypertension and cardiac hypertrophy through its receptors in the kidney. Proc Natl Acad Sci U S A 2006, 103:17985–17990.
Billet S, Aguilar F, Baudry C, Clauser E: Role of angiotensin II AT1 receptor activation in cardiovascular disease. Kidney Int 2008, 74:1379–1384.
Rossi G, Sacchetto A, Visentin P, et al.: Changes in left ventricular anatomy and function in hypertension and primary aldosteronism. Hypertension 1996, 27:1039–1045.
Delles C, Schmidt B, Muller H, et al.: Functional relevance of aldosterone for the determination of left ventricular mass. Am J Cardiol 2003, 91:297–301.
Marney A, Brown N: Aldosterone and end-organ damage. Clin Sci 2007, 113:267–278.
Israili ZH, Hall WD: Cough and angioneurotic edema associated with angiotensin-converting enzyme inhibitor therapy. A review of the literature and pathophysiology. Ann Intern Med 1992, 117:234–242.
Müller DN, Derer W, Dechend R: Aliskiren—mode of action and preclinical data. J Mol Med 2008, 86:659–662.
Brown M, Coltart J, Gunewardena K, et al.: Randomized double-blind placebo-controlled study of an angiotensin immunotherapeutic vaccine (PMD3117) in hypertensive subjects. Clin Sci 2004, 107:167–173.
Ambuhol P, Tissot A, Fulurija A, et al.: A vaccine for hypertension based on virus-like particles: preclinical efficacy and phase I safety and immunogenicity, J Hypertens 2007, 25:63–72.
Klingbeil A, Schneider M, Martus P, et al.: A meta-analysis of the effects of treatment on left ventricular mass in essential hypertension. Am J Med 2003, 115:41–46.
Dahlöf B, Devereux R, Kjeldsen S, et al.: Cardiovascular morbidity and mortality in the Losartan Intervention For Endpoint Reduction in Hypertension Study (LIFE): a randomised trial against atenolol. Lancet 2002, 359:995–1003.
Devereux RB, Dahlöf B, Gerdts E, et al.: Regression of hypertensive left ventricular hypertrophy by losartan compared with atenolol: the Losartan Intervention For Endpoint Reduction in Hypertension (LIFE) trial. Circulation 2004, 110:1456–1462.
O’Rourke MF, Safar ME: Letter regarding article by Devereux et al, “Regression of hypertensive left ventricular hypertrophy by losartan compared with atenolol: the Losartan Intervention for Endpoint Reduction in Hypertension (LIFE) trial”. Circulation 2005, 111:e377.
Hirata K, Vlachopoulos C, Adji A, O’Rourke MF: Benefits from angiotensin-converting enzyme inhibitor “beyond blood pressure lowering”: beyond blood pressure or beyond the brachial artery? J Hypertens 2005, 23:551–556.
The ONTARGET Investigators: Telmisartan, ramipril, or both in patients at high risk for vascular events. N Eng J Med 2008, 358:1547–1559.
Pitt B, Zannad F, Remme W, et al.: The effect of spironolactone on morbidity and mortality in patients with severe heart failure. N Eng J Med 1999, 341:709–717.
Zannad F, Alla F, Dousset B, et al.: Limitation of excessive extracellular matrix turnover may contribute to survival benefit in spironolactone therapy in patients with congestive heart failure: insights from the Randomized Aldactone Evaluation Study (RALES). Circulation 2000, 102:2700–2706.
Pitt B, Reichek N, Willenbrock R, et al.: Effects of eplerenone, enalapril, and eplerenone/enalapril in patients with essential hypertension and left ventricular hypertrophy. The 4E-left ventricular hypertrophy study. Circulation 2003, 108:1831–1838.
Devereux R, Palmieri V, Sharpe N, et al.: Effects of once-daily angiotensin-converting enzyme inhibition and calcium channel blockade-based antihypertensive treatment regimens on left ventricular hypertrophy and diastolic filling in hypertension: the Prospective Randomized Enalapril Study Evaluating Regression of Ventricular Enlargement (PRESERVE) trial. Circulation 2001, 104:1248–1254.
Author information
Authors and Affiliations
Corresponding author
Rights and permissions
About this article
Cite this article
Cowan, B.R., Young, A.A. Left ventricular hypertrophy and renin-angiotensin system blockade. Current Science Inc 11, 167–172 (2009). https://doi.org/10.1007/s11906-009-0030-9
Published:
Issue Date:
DOI: https://doi.org/10.1007/s11906-009-0030-9